Cullinan Oncology Inc. (CGEM)
| Bid | 6.75 |
| Market Cap | 458.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -167.38M |
| EPS (ttm) | -2.79 |
| PE Ratio (ttm) | -2.81 |
| Forward PE | -3.33 |
| Analyst | Buy |
| Ask | 8.59 |
| Volume | 469,267 |
| Avg. Volume (20D) | 451,621 |
| Open | 7.67 |
| Previous Close | 7.74 |
| Day's Range | 7.71 - 8.07 |
| 52-Week Range | 6.85 - 30.19 |
| Beta | -0.05 |
About CGEM
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody f...
Analyst Forecast
According to 9 analyst ratings, the average rating for CGEM stock is "Buy." The 12-month stock price forecast is $31.5, which is an increase of 302.30% from the latest price.
Stock Forecasts
3 months ago · seekingalpha.com
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLCCullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates. Zipalerti...